반응식
[Cl:1][C:2]1[N:3]=[C:4]([C:8]([NH:10][C@H:11]2[CH2:16][CH2:15][N:14]([C:17]3[S:18][C:19]([C:22](O)=[O:23])=[CH:20][N:21]=3)[CH2:13][C@H:12]2[O:25][CH3:26])=[O:9])[NH:5][C:6]=1[CH3:7].[CH3:27][O:28][NH2:29].CCN=C=NCCCN(C)C.Cl>CN(C1C=CN=CC=1)C>[Cl:1][C:2]1[N:3]=[C:4]([C:8]([NH:10][C@H:11]2[CH2:16][CH2:15][N:14]([C:17]3[S:18][C:19]([C:22]([NH:29][O:28][CH3:27])=[O:23])=[CH:20][N:21]=3)[CH2:13][C@H:12]2[O:25][CH3:26])=[O:9])[NH:5][C:6]=1[CH3:7]참가 물질
5
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
The same operation as in Example (1g) was performed using cis(±)-2-(4-{[(4-chloro-5-methyl-1H-imidazol-2-yl)carbonyl]amino}-3-methoxypiperidin-1-yl)-1,3-thiazole-5-carboxylic acid obtained by the method described in Example (5f) (17 mg, 0.045 mmol), O-methylhydroxylamine (15 mg, 0.18 mmol), WSC hydrochloride (0.46 g, 0.24 mmol) and DMAP (5 mg, 0.042 mmol), to obtain 3.5 mg of the title compound as a white solid (18%).
후처리
- customobtained by the method
출처 및 근거
- ORD 기록
- ord-c9b2c4772b024a168bec694340c235e7
- 출처 데이터셋
- uspto-grants-2013_09
- 특허 번호
- US08536197B2
연결된 노트
불러오는 중…